Atrial fibrillation (AFib) is the most common arrhythmia diagnosed in clinical practise. However, some patients experience no symptoms. Left untreated, the condition could have important implications.

Oral anticoagulant (OAC) therapy – either with vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) such as apixaban, dabigatran or rivaroxaban – have been shown to effectively reduce the risk of stroke, systemic embolism, and mortality in AFib patients at increased risk of stroke.

Please sign in to read more